Spironolactone in essential hypertension: Evidence against its effect through mineralocorticoid antagonism

3Citations
Citations of this article
6Readers
Mendeley users who have this article in their library.

Abstract

The effect of a six-week course of spironolactone 300 mg/ day was examined in 25 unselected patients with essential hypertension. In the blood spironolactone produced a significant rise in urea and potassium concentrations and a fall in sodium and bicarbonate concentrations. In six patients blood pressure was normal at the end of the course, while in five patients there was almost no change. Studies of the effects of spironolactone on various indices usually affected by mineralocorticoids—namely, blood electrolytes, total body potassium, and rectal electrical properties—showed no differences between responding and non-responding. patients. Mineralocorticoid excess therefore seems to be rarely responsible for essential hypertension and the influence of spironolactone cannot at present be fully explained. © 1976, British Medical Journal Publishing Group. All rights reserved.

Cite

CITATION STYLE

APA

Edmonds, C. J., & Smith, T. (1976). Spironolactone in essential hypertension: Evidence against its effect through mineralocorticoid antagonism. British Medical Journal, 1(6011), 682–684. https://doi.org/10.1136/bmj.1.6011.682

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free